Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicolas Albin

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Bulletin Du Cancer|February 25, 2018
[Onco-Hematology Division (ONCOH) ANSM: A willingness to be in tune with the needs of patients and to facilitate clinical research in a secure environment]Nicolas Albin
Cancer Chemotherapy and Pharmacology|March 5, 2019
The clinical added value of the addition of anti-CTL-4 to anti-PD-1 alone is questionable and clearly increasing toxicity regarding pivotal studies in the treatment of melanoma and renal carcinomaNicolas Albin, Adrien Monard, Jérémy Lapiere
European Journal of Cancer (Oxford, England : 1990)|August 22, 2021
Response to the letter: Re: Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 yearsEmmanuelle Jacquet, Adrien Monard, Nicolas Albin
La Revue Du Praticien|December 13, 2022
[Early access to innovative drugs, ethical impacts]Nicolas Albin, Emmanuelle Jacquet, Adrien Monard
Therapie|January 8, 2019
Nicolas Albin, Frédéric Chassagnol, Jean-François Bergmann, et al.
Bulletin Du Cancer|March 5, 2018
[Precision medicine: A major step forward in specific situations, a myth in refractory cancers?]Nicolas Albin, Anne Mc Leer, Linda Sakhri
Therapie|February 13, 2019
Early access to health products in France: Major advances of the French "Conseil stratégique des industries de santé" (CSIS) to be implemented (modalities, regulations, funding)Nicolas Albin, Frédéric Chassagnol, Jean-François Bergmann, et al.
Bulletin Du Cancer|January 1, 2022
[Administrative delays of temporary recommendation for use: Impact on access to innovation in melanoma]Cécile Auger, Bernard Guillot, Adrien Monard, et al.
Clinical and Translational Gastroenterology|October 7, 2024
Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Gastric Cancer in a Real-World Setting: A Nationwide Cohort StudyHugo Jourdain, Nicolas Albin, Adrien Monard, et al.
The Lancet Regional Health. Europe|October 27, 2025
PD-L1 inhibitors combined with chemotherapy for extensive-stage small cell lung cancer: a French nationwide cohort studyHugo Jourdain, Nicolas Albin, Adrien Monard, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Bulletin Du Cancer|February 25, 2018
[Onco-Hematology Division (ONCOH) ANSM: A willingness to be in tune with the needs of patients and to facilitate clinical research in a secure environment]Nicolas Albin
Cancer Chemotherapy and Pharmacology|March 5, 2019
The clinical added value of the addition of anti-CTL-4 to anti-PD-1 alone is questionable and clearly increasing toxicity regarding pivotal studies in the treatment of melanoma and renal carcinomaNicolas Albin, Adrien Monard, Jérémy Lapiere
European Journal of Cancer (Oxford, England : 1990)|August 22, 2021
Response to the letter: Re: Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 yearsEmmanuelle Jacquet, Adrien Monard, Nicolas Albin
La Revue Du Praticien|December 13, 2022
[Early access to innovative drugs, ethical impacts]Nicolas Albin, Emmanuelle Jacquet, Adrien Monard
Therapie|January 8, 2019
Nicolas Albin, Frédéric Chassagnol, Jean-François Bergmann, et al.
Bulletin Du Cancer|March 5, 2018
[Precision medicine: A major step forward in specific situations, a myth in refractory cancers?]Nicolas Albin, Anne Mc Leer, Linda Sakhri
Therapie|February 13, 2019
Early access to health products in France: Major advances of the French "Conseil stratégique des industries de santé" (CSIS) to be implemented (modalities, regulations, funding)Nicolas Albin, Frédéric Chassagnol, Jean-François Bergmann, et al.
Bulletin Du Cancer|January 1, 2022
[Administrative delays of temporary recommendation for use: Impact on access to innovation in melanoma]Cécile Auger, Bernard Guillot, Adrien Monard, et al.
Clinical and Translational Gastroenterology|October 7, 2024
Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Gastric Cancer in a Real-World Setting: A Nationwide Cohort StudyHugo Jourdain, Nicolas Albin, Adrien Monard, et al.
The Lancet Regional Health. Europe|October 27, 2025
PD-L1 inhibitors combined with chemotherapy for extensive-stage small cell lung cancer: a French nationwide cohort studyHugo Jourdain, Nicolas Albin, Adrien Monard, et al.
Pageof 2